Ruboxistaurin mesylate (LY333531) is a bisindolylmaleimide inhibitor of a PKC isoform - protein kinase C beta(PKC-β). Its development to prevent complications in type 2 diabetes was halted during phase III trials in diabetic retinopathy due some unfavourable primary end point data on retinopathy progression even though it may have reduced visual loss.
- ↑ Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Archives of ophthalmology. 2007 Mar; 125(3):318-24.(Link to article – subscription may be required.)
- ↑ Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati L, Zhi XE. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology. 2006 Dec; 113(12):2221-30.(Link to article – subscription may be required.)